---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-008496"
form_type: "8-K"
ticker: "ARQT"
cik: "0001787306"
company_name: "Arcutis Biotherapeutics, Inc."
filed_at: "2024-03-04T23:59:59+00:00"
generated_at: "2026-06-05T04:50:24.594565+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcutis raises ~$161.6M in public offering of 18.2M shares at $9.50

## Summary
- Issued ~18.2M shares at $9.50 via underwritten public offering, raising ~$161.6M net.
- Underwriters fully exercised 30-day option to purchase additional 2,368,421 shares on Feb 29, 2024.
- Net proceeds intended to fund commercialization, development, and approval for atopic dermatitis, scalp psoriasis, and psoriasis expansion.
- Offering conducted under existing Form S-3 shelf registration (File No. 333-276794).

## SEC filing metadata
- accession: 0001628280-24-008496
- form_type: 8-K
- ticker: ARQT
- cik: 0001787306
- company_name: Arcutis Biotherapeutics, Inc.
- filed_at: 2024-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787306/000162828024008496/0001628280-24-008496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787306/000162828024008496/arqt-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-008496
- JSON: https://secwatch.observer/filing/0001628280-24-008496.json
- Plain text: https://secwatch.observer/filing/0001628280-24-008496.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.